VISTA Phase II Trial: Oral Elecoglipron Delivers 11.8% Weight Loss at 36 Weeks Without Dosing Restrictions

The VISTA study randomized 310 participants across seven countries to Elecoglipron doses from 5 mg to 75 mg or placebo for 36 weeks. Higher doses produced progressively greater reductions, with the 75 mg arm reaching 10.5% loss by week 26 and 11.8% by week 36; 89% achieved at least 5% loss versus 16% on placebo. Weight loss had not plateaued, and secondary improvements occurred in blood pressure and C-reactive protein. Gastrointestinal adverse events remained the dominant signal but were mostly mild and early.

Compared with injectable semaglutide in the STEP 1 trial (NEJM 2021), which reported 14.9% mean loss at 68 weeks, Elecoglipron offers administration flexibility that could improve adherence for patients averse to needles or refrigeration. Unlike oral semaglutide, which requires strict fasting, Elecoglipron has no food or water constraints, addressing a documented barrier to persistence. However, the shorter duration and absence of cardiovascular endpoint data leave open whether efficacy will match or exceed established agents in longer trials.

Phase III programs must now establish durability beyond 36 weeks, confirm major adverse cardiovascular event reduction, and quantify real-world adherence and cost offsets versus weekly injectables. Regulatory filings will hinge on whether the convenience advantage translates into higher persistence rates sufficient to offset potentially lower peak efficacy. Payers will watch closely for head-to-head data that could shift formulary positioning within 18-24 months.